Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: The Role of a Negative Confirmatory MRI-US Fusion Biopsy.

Bloom JB, Hale G, Gold SA, Rayn K, Smith C, Mehralivand S, Czarniecki M, Valera V, Wood BJ, Merino M, Choyke PL, Parnes HL, Turkbey B, Pinto PA.

J Urol. 2018 Jul 28. pii: S0022-5347(18)43606-3. doi: 10.1016/j.juro.2018.07.051. [Epub ahead of print]

PMID:
30063928
2.

A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.

Mehralivand S, Shih JH, Rais-Bahrami S, Oto A, Bednarova S, Nix JW, Thomas JV, Gordetsky JB, Gaur S, Harmon SA, Siddiqui MM, Merino MJ, Parnes HL, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

JAMA Oncol. 2018 May 1;4(5):678-685. doi: 10.1001/jamaoncol.2017.5667.

PMID:
29470570
3.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1549-1557. doi: 10.1158/1055-9965.EPI-17-0503. Epub 2017 Jul 28.

4.

Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort.

Nguyen MM, Martinez JA, Hsu CH, Sokoloff M, Krouse RS, Gibson BA, Nagle RB, Parnes HL, Cordova C, Chow HS.

Eur J Cancer Prev. 2018 Nov;27(6):557-562. doi: 10.1097/CEJ.0000000000000394.

PMID:
28692586
5.

Commentary: Prostate cancer screening-A long run for a short slide.

Parnes HL.

Semin Oncol. 2017 Feb;44(1):57-59. doi: 10.1053/j.seminoncol.2017.02.011. Epub 2017 Feb 20. No abstract available.

PMID:
28395764
6.

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.

Gee JR, Saltzstein DR, Kim K, Kolesar J, Huang W, Havighurst TC, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House MG, Parnes HL, Bailey HH.

Cancer Prev Res (Phila). 2017 May;10(5):298-307. doi: 10.1158/1940-6207.CAPR-16-0167. Epub 2017 Mar 21.

7.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2017 Jun;77(8):908-919. doi: 10.1002/pros.23346. Epub 2017 Mar 20.

8.

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim KM, Havighurst T, Slaton J, House MG, Parnes HL, Bailey HH.

Am J Clin Exp Urol. 2016 Sep 20;4(2):17-27. eCollection 2016.

9.

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.

Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA.

Oncoimmunology. 2016 Jul 1;5(8):e1197459. doi: 10.1080/2162402X.2016.1197459. eCollection 2016 Aug.

10.

Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.

Frye TP, George AK, Kilchevsky A, Maruf M, Siddiqui MM, Kongnyuy M, Muthigi A, Han H, Parnes HL, Merino M, Choyke PL, Turkbey B, Wood B, Pinto PA.

J Urol. 2017 Mar;197(3 Pt 1):640-646. doi: 10.1016/j.juro.2016.08.109. Epub 2016 Sep 6.

PMID:
27613356
11.

A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.

Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, Yu Y, Merino MJ, Madan RA, Parnes HL, Steinberg SM, Rodriguez BW, Seon BK, Gulley JL, Arlen PM, Dawson NA, Figg WD, Dahut WL.

Clin Genitourin Cancer. 2017 Feb;15(1):77-85. doi: 10.1016/j.clgc.2016.05.010. Epub 2016 May 27.

PMID:
27328856
12.

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P.

EBioMedicine. 2016 May;7:85-93. doi: 10.1016/j.ebiom.2016.03.047. Epub 2016 Apr 7.

13.

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD.

Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10.

14.

Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.

Siddiqui MM, George AK, Rubin R, Rais-Bahrami S, Parnes HL, Merino MJ, Simon RM, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

J Natl Cancer Inst. 2016 Apr 29;108(9). pii: djw039. doi: 10.1093/jnci/djw039. Print 2016 Sep.

15.

Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer.

Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL.

J Nucl Med. 2016 Jun;57(6):886-92. doi: 10.2967/jnumed.115.166512. Epub 2016 Jan 21.

16.

Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.

Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA.

Prostate. 2016 May;76(6):565-74. doi: 10.1002/pros.23147. Epub 2016 Jan 15.

17.

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Murtola TJ, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. Epub 2015 Dec 29.

18.

Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

Nash SH, Till C, Song X, Lucia MS, Parnes HL, Thompson IM Jr, Lippman SM, Platz EA, Schenk J.

Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1507-15. doi: 10.1158/1055-9965.EPI-15-0394. Epub 2015 Aug 12.

19.

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippmann SM, Parnes HL, Dluzniewski PJ, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2015 Sep;75(13):1403-18. doi: 10.1002/pros.23021. Epub 2015 Jun 5.

20.

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD.

PLoS One. 2015 May 8;10(5):e0126672. doi: 10.1371/journal.pone.0126672. eCollection 2015.

21.

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM, Goodman PJ, Thompson IM, Lippman SM, Lucia MS, Parnes HL, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Prostate Cancer Prostatic Dis. 2015 Sep;18(3):264-9. doi: 10.1038/pcan.2015.19. Epub 2015 May 5.

22.

Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.

Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA.

Cancer Prev Res (Phila). 2015 Jul;8(7):590-6. doi: 10.1158/1940-6207.CAPR-14-0398. Epub 2015 Apr 29.

23.

Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.

Okoro C, George AK, Siddiqui MM, Rais-Bahrami S, Walton-Diaz A, Shakir NA, Rothwax JT, Raskolnikov D, Stamatakis L, Su D, Turkbey B, Choyke PL, Merino MJ, Parnes HL, Wood BJ, Pinto PA.

J Endourol. 2015 Oct;29(10):1115-21. doi: 10.1089/end.2015.0027. Epub 2015 Jul 23.

24.

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn G, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ.

Cancer Prev Res (Phila). 2015 Oct;8(10):879-87. doi: 10.1158/1940-6207.CAPR-14-0324. Epub 2015 Apr 14.

25.

Pilot study on the bioactivity of vitamin d in the skin after oral supplementation.

Curiel-Lewandrowski C, Tang JY, Einspahr JG, Bermudez Y, Hsu CH, Rezaee M, Lee AH, Tangrea J, Parnes HL, Alberts DS, Chow HH.

Cancer Prev Res (Phila). 2015 Jun;8(6):563-9. doi: 10.1158/1940-6207.CAPR-14-0280. Epub 2015 Apr 2.

26.

Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.

Walton Diaz A, Shakir NA, George AK, Rais-Bahrami S, Turkbey B, Rothwax JT, Stamatakis L, Hong CW, Siddiqui MM, Okoro C, Raskolnikov D, Su D, Shih J, Han H, Parnes HL, Merino MJ, Simon RM, Wood BJ, Choyke PL, Pinto PA.

Urol Oncol. 2015 May;33(5):202.e1-202.e7. doi: 10.1016/j.urolonc.2015.01.023. Epub 2015 Mar 6.

PMID:
25754621
27.

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.

Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Ambrosone CB, Thompson IM.

Urology. 2015 Mar;85(3):616-20. doi: 10.1016/j.urology.2014.11.024.

28.

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA.

JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.

29.

Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW.

JAMA Dermatol. 2015 Feb;151(2):170-7. doi: 10.1001/jamadermatol.2014.2734.

PMID:
25427282
30.

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.

31.

Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL Jr, Thompson IM.

Cancer Prev Res (Phila). 2014 Sep;7(9):886-95. doi: 10.1158/1940-6207.CAPR-14-0058. Epub 2014 Jun 24.

32.

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):847-56. doi: 10.1158/1055-9965.EPI-13-1126. Epub 2014 Apr 18.

33.

Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial.

Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1494-504. doi: 10.1158/1055-9965.EPI-14-0115. Epub 2014 Apr 14.

34.

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.

Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH.

J Oncol Pharm Pract. 2015 Apr;21(2):128-31. doi: 10.1177/1078155214528552. Epub 2014 Mar 17.

35.

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA.

J Natl Cancer Inst. 2014 Mar;106(3):djt456. doi: 10.1093/jnci/djt456. Epub 2014 Feb 22.

36.

Prostate cancer prevention: agent development strategies.

Parnes HL, House MG, Tangrea JA.

Recent Results Cancer Res. 2014;202:121-31. doi: 10.1007/978-3-642-45195-9_15.

PMID:
24531786
37.

Phase III prostate cancer chemoprevention trials.

Parnes HL, Brawley OW, Minasian LM, Ford LG.

Recent Results Cancer Res. 2014;202:73-7. doi: 10.1007/978-3-642-45195-9_9.

PMID:
24531780
38.

Statin drug use is not associated with prostate cancer risk in men who are regularly screened.

Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM Jr, Kristal AR.

J Urol. 2014 Aug;192(2):379-84. doi: 10.1016/j.juro.2014.01.095. Epub 2014 Feb 8.

39.

Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.

Pinsky PF, Parnes HL, Andriole G.

BJU Int. 2014 Feb;113(2):254-9. doi: 10.1111/bju.12368. Epub 2013 Nov 21.

40.

Long-term survival of participants in the prostate cancer prevention trial.

Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG.

N Engl J Med. 2013 Aug 15;369(7):603-10. doi: 10.1056/NEJMoa1215932.

41.

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR.

J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41. doi: 10.1093/jnci/djt174. Epub 2013 Jul 10.

42.

Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer.

Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, Hoang AN, Vourganti S, Truong H, Shuch B, Parnes HL, Turkbey B, Choyke PL, Wood BJ, Simon RM, Pinto PA.

Cancer. 2013 Sep 15;119(18):3359-66. doi: 10.1002/cncr.28216. Epub 2013 Jul 2.

43.

Prostate cancer prevention: strategies for agent development.

Parnes HL, House MG, Tangrea JA.

Curr Opin Oncol. 2013 May;25(3):242-51. doi: 10.1097/CCO.0b013e32835fc8d4. Review.

PMID:
23518594
44.

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.

BJU Int. 2013 Jun;111(8):1269-80. doi: 10.1111/j.1464-410X.2012.11667.x. Epub 2013 Feb 18.

45.

Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial.

Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M.

Cancer Prev Res (Phila). 2013 Feb;6(2):91-9. doi: 10.1158/1940-6207.CAPR-12-0250. Epub 2013 Jan 11.

46.

Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion.

Nam RK, Oliver TK, Vickers AJ, Thompson I, Kantoff PW, Parnes HL, Loblaw A, Roth BJ, Williams J, Temin S, Basch E.

J Oncol Pract. 2012 Sep;8(5):315-7. doi: 10.1200/JOP.2012.000715. No abstract available.

47.

Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Black A, Parnes HL, Grubb R, David Crawford E, Miller A, Reding D, Andriole G.

Cancer Epidemiol. 2012 Dec;36(6):e401-6. doi: 10.1016/j.canep.2012.08.008. Epub 2012 Sep 19.

48.

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP.

Prostate. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10.

49.

Active surveillance for prostate cancer: past, present and future.

Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes HL.

Curr Opin Oncol. 2012 May;24(3):243-50. doi: 10.1097/CCO.0b013e3283527f99. Review.

PMID:
22450149
50.

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.

Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.

PMID:
22326924

Supplemental Content

Loading ...
Support Center